Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs
Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission.